Abstract
Our objective was to study the relationship between dispensed aspirin, nonaspirin nonsteroidal antiinflammatory drugs (NSAIDs), steroidal antiinflammatory drugs (SAIDs), acetaminophen, calcium, psyllium, and multivitamin preparations and the risk for subsequent colorectal adenoma and adenocarcinoma. The design was a case-control study. The patient population was from a large municipal teaching hospital in Atlanta, Georgia. In logistic regression models, the risk of colorectal adenoma or adenocarcinoma decreased in the first two years of continuous NSAID use in a linear, time-dependent manner. The risk of colorectal neoplasia after two years of continuous NSAID use was reduced significantly (P<0.01) as compared to nonusers. Risk reduction appeared greater for adenocarcinoma than adenoma. The use of SAIDs, calcium, multivitamins, and psyllium, as prescribed to our patient population during the mean six-year study period, conferred no measurable risk reduction. These results suggest that in prospective chemoprevention trials, a significant risk reduction can be expected after only two years of aspirin use, in doses similar to those recommended for the prevention of cardiovascular disease, or nonaspirin. NSAIDs, in doses commonly prescribed for the management of musculoskeletal pain. The results also imply that any short-term reduction in the incidence of colorectal adenoma detected in a phase II trial would underestimate the chemopreventive effect of NSAIDs on the risk of adenocarcinoma.
Similar content being viewed by others
References
Boring CC, Squires TS, Tong T, Montgomery S: Cancer statistics, 1994. CA 44:27–43, 1994
Potter JD, Slattery ML, Bostick RM, Gapstur SM: Colon cancer: A review of the epidemiology. Epidemiol Rev 15:499–545, 1993
Zimmerman J: Does dietary calcium supplementation reduce the risk of colon cancer? Nutr Rev 51:109–112, 1993
Dwyer J: Dietary fiber and colorectal cancer risk. Nutr Rev 51:147–155, 1993
Ausman LM: Fiber and colon cancer: Does the current evidence justify a preventive policy? Nutr Rev 51:57–63, 1993
Baron JA, Greenburg ER: Could aspirin really prevent colon cancer. N Engl J Med 325:1644–1646, 1991
Farmer KC, Goulston K, Mcrae F: Aspirin and non-steroidal anti-inflammatory drug in the chemoprevention of colorectal cancer. Med J Aust 159:649–650, 1993
Greenburg ER, Baron JA: Prospects for preventing colorectal cancer death. J Natl Cancer Inst 85:1182–1183, 1993
Paganini-Hill A: Aspirin and colorectal cancer. Br Med J 307:278–279, 1993
Waterhouse DM, Brenner D: Aspirin, NSAIDS and risk reduction of colorectal cancer Arch Interm Med 154:366–367, 1994
Baron JA, Adami AO: A broad anticancer effect of aspirin? Epidemiology 5:133–134, 1994
Marnett LJ: Aspirin and the potential role of prostaglandins in colon cancer. Cancer Res 52:5575–5589, 1992
Earnest DJ, Hixson LJ, Alberts DS: Pirioxicam and other cyclooxygenase inhibitors: A potential for cancer chemoprevention. J Cell Biochem Suppl 161:156–166, 1992
Turner D, Berkel HJ: Nonsteroidal anti-inflammatory drugs for the prevention of colon cancer. Can Med Assoc J 149:595–602, 1993
Waddell WR: The effect of sulindac on colon polyps: Circumvention of a transformed phenotype—a hypothesis. J Surg Oncol 55:52–55, 1994
Kune GA, Kune S, Watson LF: Colorectal cancer risk, chronic illnesses, operations, and medications: Case-control results from the Melbourne colorectal cancer study. Cancer Res 48:4399–4404, 1988
Rosenburg L, Palmer RJ, Zauber AG, Warshauer ME, Stolley PD: A hypothesis: Nonsteroidal anti-inflammatory drugs reduce the incidence of large-bowel cancer. J Natl Cancer Inst 83:355–358, 1991
Peleg I, Maibach HT, Brown SH, Wilcox, CM: Aspirin and nonsteroidal antiinflammatory drug use and the risk of subsequent colorectal cancer. Arch Intern Med 154:394–399, 1994
Suh O, Mettlin C, Petrelli NJ: Aspirin use, cancer and polyps of the large bowel. Cancer 72:1171–1177, 1993
Logan RFA, Little J, Hatwin PG, Hardcastle JD: Effect of aspirin and nonsteroidal anti-inflammatory drugs on the risk of colorectal adenomas: Case-control study of subjects participating in the Nottingham faecal occult blood screening programme. Br Med J 307:285–288, 1993
Greenburg ER, Baron JA, Freeman DH, Mandel JS, Haile R: Reduced risk of large bowel adenomas among aspirin users. J Natl Cancer Inst 85:912–916, 1993
Thun MJ, Nambroodiri MN, Heath CW Jr: Aspirin use and reduced risk of fatal colon cancer. N Engl J Med 325:1593–1596, 1991
Thun MJ, Calle EE, Nambroodiri MM, Heath CW Jr., et al: Risk factors for fatal colon cancer in a large prospective study. J Natl Cancer Inst 84:1491–1500, 1992
Schreinemachers DM, Everson RB: Aspirin use and lung, colon, and breast cancer incidence in a prospective study. Epidemiology 5:138–146, 1994
Paganini-Hill A, Chao A, Ross RK, Henderson BE: Aspirin use and chronic diseases: A cohort study in the elderly. Br Med J 299:1247–1250, 1989
Paganini-Hill A, Hsu G, Ross RK, Henderson BE: Aspirin use and incidence of large-bowel in a California retirement community J Natl Cancer Inst 83:1182–1183, 1991 (letter)
Paganini-Hill A, Hsu G, Ross RK, Henderson BE: Aspirin use and reduced risk of fatal colon cancer. N Engl J Med 326:1290, 1992 (letter)
Gann PH, Manson JE, Glynn RJ, Buring JE, Hennekens CH: Low-dose aspirin use and the incidence of colorectal tumors in a randomized trial. J Natl Cancer Inst 85:1220–1224, 1993
Muscat JE, Stellman SD, Wynder EL: Nonsteroidal anti-inflammatory drugs and colorectal cancer. Cancer 74:1846–1857, 1994
Tempero MA: Progress in chemoprevention of gastrointestinal cancer. Curr Opin Oncol 3:719–726, 1991
Walker HK, Camp H, Brown S: The THERESA on-line medical record. Presentation to the Society of General Internal Medicine 14th Annual Meeting May 1, 1990
BMDP Statistical Software Inc. v. 1993, Los Angeles, California 90025
Bedenne L, Faivre J, Boutron MC, et al: Adenoma-carcinoma sequence or “de novo” carcinogenesis? A study of adenomatous remenants in a population-based series of large bowel cancer. Cancer 69:883–888, 1992
Horm JW, Asire AJ, Young AJ, Jr. Pollack ES: SEER program: Cancer incidence and mortality in the United States 1973–1981. NIH Publication 85-1873, Bethesda, Maryland 20205, National Cancer Institute
Smigel K: Aspirin's next conquest: Does it prevent colorectal cancer? J Natl Cancer Inst 86:166–168, 1994
Cairns J, Cohen L, Colton T, et al: Issues in the early termination of the aspirin component of the Physicians' Health Study. Ann Epidemiol 1:395–405, 1991
Physician's Desk Reference. Medical Economics Data 1992, p 1447
DuBois RN: Nonsteroidal anti-inflammatory drug use and sporadic colorectal adenoma. Gastroenterology 108:A478, 1995
Hanif R, Pittas A, Feng Y, Koutsos MI, Shiff SJ, Staiano-Coico L, Rigas B: NSAIDs inhibit the cell growth of colon cancer cell lines by a prostaglandin independent pathway. Gastroenterology 108:A478, 1995
Waddell WR, Ganser GF, Cerise EJ, Loughry RW: Sulindac for polyposis of the colon. Am J Surg 157:175–179, 1989
Rigau J, Pique JM, Rubio E, Planas R, Tarrech JM, Bordas JM: Effects of long-term sulindac therapy on colonic polyposis. Ann Intern Med 115:952–955, 1991
Giardiello FM, Hamilton SR, Krush AJ, et al: Treatment of colonic and rectal adenomas with sulindac in familial adenomatous polyposis. N Engl J Med 328:1313–1316, 1993
Labayle D, Fischer D, Viehl P, Drouhin F, Pariente F, Bories C, Duhamel O, Trousset M, Attali P: Sulindac causes regression of rectal polyps in familial adenomatous polyposis. Gastroenterology 101:635–639, 1991
Rickert RR, Auerbach O, Garfinkel L, Hammond EC, Frasca JM: Adenomatous lesions of the large bowel. Cancer 43:1847–1857, 1979
Eddy DM: Screening for colorectal cancer. Ann Intern Med 113:373–384, 1990
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Peleg, I.I., Lubin, M.F., Cotsonis, G.A. et al. Long-term use of nonsteroidal antiinflammatory drugs and other chemopreventors and risk of subsequent colorectal neoplasia. Digest Dis Sci 41, 1319–1326 (1996). https://doi.org/10.1007/BF02088554
Received:
Revised:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF02088554